Service resources: Oncology
The Novartis Breast Cancer Health Inequalities Tool
The Novartis Breast Cancer Health Inequalities (BC HI) Tool brings together a range of datasets to build a greater understanding of the drivers behind the current variation that exists across breast cancer pathways, as well as in breast cancer patient outcomes, at a national and local level across England.
The BC HI interactive dashboard-based tool can highlight relationships between breast cancer and socioeconomic factors, such as deprivation, ethnicity and rurality, at different stages of disease and within different age groups.
The BC HI Tool showcases a variety of real-world data, such as cancer referrals, stage of diagnosis, survival and quality of life metrics, as well as an in-depth analysis of Hospital Episode Statistics data to highlight disparity, variation and unmet need, both nationally and at a system level (Cancer Alliance/ICS).
System inequalities
Quality of life
Cancer survival
Access the interactive Novartis Breast Cancer Health Inequalities Tool
Insights from the BC HI Tool can support the goal of reducing health inequalities across the NHS at a national and system level, aligning with the NHS Core20PLUS5 ambition. Drawing on deprivation data from the Office for National Statistics, the tool maps breast cancer outcomes in relation to deprivation at a national, Cancer Alliance and ICS level, providing a breakdown of outcomes data across deprivation quintiles.
Access the Novartis Health Inequalities Pledge
This dashboard has been created by Wilmington Healthcare and funded by Novartis Pharmaceuticals UK Limited, using data obtained from NHS England and publicly available sources.
Breast Cancer Health Inequalities Tool supporting user guide
BC HI, Breast Cancer Health Inequalities; ICS, integrated care system; NHS, National Health Service.
UK | February 2025 | FA-11223209
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
